Post-Transplant Drug Study for ALL and NHL
Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma
HEALTHY PARTICIPANTS: No
TYPE: Drug Study (Inotuzumab Ozogamicin)
Learn More About This Research Study
For more information, please contact study coordinator Rose Purgert, RN by completing the online form below.
The purpose of this study is to evaluate overall disease free survival post stem cell transplant. There are two phases of this study using a drug called inotuzumab ozogamicin. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which targets and delivers chemotherapy directly to residual cancer cells in acute lymphocytic leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL). Phase I of this study aims to identify what doses of inotuzumab ozogamicin can safely be given to subjects post-stem cell transplant without having too many side effects. Phase II of this study aims to further identify what side effects are seen with inotuzumab ozogamicin post-transplant.
Who Can Participate
Participants must be between 16 and 75 years of age and diagnosed with either CD22-positive ALL or CD22-positive NHL (includes DLBCL, transformed indolent lymphoma, CLL/SLL with Richter’s transformation, and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements). Participants with these conditions who are expecting to have or who have recently received a stem cell transplant may be eligible to participate in this study.